BiotechTube

Fosmanogepix IV infusion + Standard of care antifungal therapy + Fosmanogepix oral tablet

Phase 3Recruiting
0 views this week 0 watching⚡ Active🔬Featured in Small-Cap Pipeline Watch
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Invasive Mold Infections

Conditions

Invasive Mold Infections

Trial Timeline

Aug 26, 2025 → Feb 1, 2028

NCT ID
NCT06925321

About Fosmanogepix IV infusion + Standard of care antifungal therapy + Fosmanogepix oral tablet

Fosmanogepix IV infusion + Standard of care antifungal therapy + Fosmanogepix oral tablet is a phase 3 stage product being developed by Basilea Pharmaceutica for Invasive Mold Infections. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06925321. Target conditions include Invasive Mold Infections.

What happened to similar drugs?

4 of 20 similar drugs in Invasive Mold Infections were approved

Approved (4) Terminated (2) Active (15)
🔄Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
🔄Micafungin + fluconazoleAstellas PharmaPhase 3
🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
❌Micafungin + PlaceboAstellas PharmaPhase 3
✅MicafunginAstellas PharmaApproved
🔄Olorofim + AmBisome®ShionogiPhase 3
🔄Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06925321Phase 3Recruiting

Competing Products

20 competing products in Invasive Mold Infections

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
39
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Trastuzumab deruxtecan + DurvalumabDaiichi SankyoPhase 2
42
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPre-clinical
26
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Pudexacianinium chlorideAstellas PharmaPhase 2
35
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
26
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Isavuconazonium sulfate + Isavuconazonium sulfateAstellas PharmaPhase 2
35
Micafungin + Systemic antifungal therapyAstellas PharmaPhase 2
27
MicafunginAstellas PharmaPre-clinical
26
Micafungin + PlaceboAstellas PharmaPhase 3
32
MicafunginAstellas PharmaApproved
35
Olorofim + AmBisome®ShionogiPhase 3
44
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
44
SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3
47